EMEA-coordinated PROTECT project has been accepted for funding

The European Medicines Agency (EMEA)The PROTECT project (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) has been accepted for funding by the Innovative Medicines Initiative Joint Undertaking (IMI JU). PROTECT is a collaborative European project aiming to develop innovative methods in pharmacoepidemiology and pharmacovigilance.

The European Medicines Agency (EMEA) coordinates the project and manages a multi-national consortium of 29 public and private partners.

In April 2008, the IMI JU issued its 1st Call offering research grants for projects to be jointly conducted by research groups comprising mainly public organisations (including academia, competent authorities, non-profit patient organisations and small/medium-sized enterprises) and EFPIA companies. Of the 18 call topics, PROTECT addresses topic no 6: Improving and strengthening the monitoring of the benefit/risk of medicines marketed in the EU.

PROTECT will run over five years, with a total funding of EUR 20 million. Half of the funding will be in-kind contributions from the participating EFPIA companies. The target start date of the project is September 2009.

PROTECT will look at limitations of current methods used in pharmacovigilance and pharmacoepidemiology in order to strengthen the monitoring of the benefit/risk balance of medicines marketed in Europe. A set of innovative tools and methods will be developed and validated in specialised Work Packages, including: (i) modern tools of communication to directly collect data from consumers of medicines; (ii) improved tools for early and proactive detection of signals; (iii) a framework for the design, conduct and analysis of pharmacoepidemiological studies; and (iv) methods for continuous benefit/risk monitoring, with a particular emphasis on graphical methods to display benefit/risk profiles.

In addition to PROTECT, the EMEA also contributes to the IMI-funded project Eu2P, which focuses on the development of a comprehensive and flexible pan-European training and education programme for both specialists and non-specialists in the fields of pharmacoepidemiology and pharmacovigilance.

  • The IMI JU is a newly established European body of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). More information on the IMI JU is available at: http://www.imi-europe.org
  • This press release, together with other information on the work of the EMEA, can be found on the EMEA website: http://www.emea.europa.eu

Most Popular Now

How SARS-CoV-2 mutates to escape antibody binding

In a recurring pattern of evolution, SARS-CoV-2 evades immune responses by selectively deleting small bits of its genetic sequence, according to new research from the Uni...

Anticancer drug may improve outcome for severe COV…

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China ...

Pfizer and BioNTech commence global clinical trial…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in a global Phase 2/3 study to further evaluate the saf...

GSK and Vir Biotechnology expand coronavirus colla…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) have signed a binding agreement to expand their existing collaboration to include the resear...

One dose of COVID-19 vaccine provokes strong immun…

Although clinical trial data are encouraging, real-world evidence with regard to the COVID-19 vaccine remains scarce. In particular, response to the vaccine among those p...

Johnson & Johnson announces submission of appl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen Biotech, Inc., has submitted an application to the U.S. Food and Drug Administration (FDA) requesting E...

Could a nasal spray prevent coronavirus transmissi…

A nasal antiviral created by researchers at Columbia University Vagelos College of Physicians and Surgeons blocked transmission of SARS-CoV-2 in ferrets, suggesting the n...

European Commission purchases additional 150 milli…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission purchased an...

Johnson & Johnson Announces Submission to Worl…

Johnson & Johnson (NYSE: JNJ) (the Company) announced that Janssen-Cilag International N.V. has submitted for Emergency Use Listing (EUL) to the World Health Organization...

Neandertal gene variants both increase and decreas…

Last year, researchers at Karolinska Institutet in Sweden and the Max Planck Institute for Evolutionary Anthropology in Leipzig, Germany showed that a major genetic risk ...

CureVac initiates rolling submission with European…

CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today annou...

Pfizer and BioNTech publish data from in vitro stu…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication in Nature Medicine of data from in vitro studies that demonstrate that sera from in...